Press Releases Transgene

Equities

TNG

FR0005175080

Market Closed - Euronext Paris Other stock markets 09:05:05 02/05/2024 pm IST			5-day change	1st Jan Change
1.22 ^EUR	-1.61%		-7.72%	-10.95%

10/04	Transgene: presents vaccine results at AACR	CF
28/03	Transgene CFO Steps Down; Successor Assumes Office	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Availability of Preparatory Documents for the Combined General Meeting of May 15, 2024	24/04	GL
Availability of Transgene's 2023 Universal Registration Document	11/04	GL
Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024	09/04	GL
Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025	27/03	GL
Transgene appoints Lucie Larguier as Chief Financial Officer and Christelle Schwoerer as Chief Human Resources Officer	27/03	GL
Transgene Announces Upcoming Investor Meetings	18/03	GL
Transgene Announces Upcoming Investor Meetings	18/03	AQ
Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024	06/03	GL
Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024	06/03	AQ
Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050	05/03	BU
Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050	05/03	GL
Transgene Further Strengthens Management Team with Appointment of James Wentworth as Chief Business Officer	22/01	GL
Transgene Further Strengthens Management Team with Appointment of James Wentworth as Chief Business Officer	22/01	AQ
Transgene Announces Financial Calendar for 2024	22/01	GL
Transgene Announces Financial Calendar for 2024	22/01	AQ
Transgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050	08/01	GL
Transgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050	08/01	AQ
Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of December 31, 2023	04/01	GL
Transgene announces its next meetings with investors	22/12	AQ
BioInvent and Transgene, First patient treated in Part B of Phase 1 trial assessing the novel oncolytic virus BT-001 in combination with KEYTRUDA	11/23/11	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Transgene

Equities

TNG

FR0005175080

Press Releases

Filters